Geode Capital Management
DMAC icon

Geode Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Geode Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.3M Buy
894,115
+113,599
+15% +$698K ﹤0.01% 2793
2026
Q1 		$5.29M Buy
780,516
+16,261
+2% +$129K ﹤0.01% 2706
2025
Q4 		$6.08M Buy
764,255
+52,437
+7% +$392K ﹤0.01% 2668
2025
Q3 		$4.89M Buy
711,818
+81,670
+13% +$443K ﹤0.01% 2792
2025
Q2 		$2.46M Buy
630,148
+314,407
+100% +$1.23M ﹤0.01% 3074
2025
Q1 		$1.2M Buy
315,741
+9,990
+3% +$57.1K ﹤0.01% 3243
2024
Q4 		$1.66M Sell
305,751
-1,207
-0.4% -$5.69K ﹤0.01% 3198
2024
Q3 		$1.29M Buy
306,958
+70,070
+30% +$259K ﹤0.01% 3266
2024
Q2 		$699K Sell
236,888
-2,347
-1% -$6.44K ﹤0.01% 3447
2024
Q1 		$663K Buy
239,235
+20,457
+9% +$59.4K ﹤0.01% 3515
2023
Q4 		$621K Hold
218,778
– – ﹤0.01% 3533
2023
Q3 		$565K Buy
218,778
+33,908
+18% +$109K ﹤0.01% 3555
2023
Q2 		$799K Hold
184,870
– – ﹤0.01% 3441
2023
Q1 		$283K Hold
184,870
– – ﹤0.01% 3887
2022
Q4 		$292K Sell
184,870
-349
-0.2% -$470 ﹤0.01% 3901
2022
Q3 		$229K Buy
185,219
+8,197
+5% +$12.8K ﹤0.01% 4125
2022
Q2 		$357K Buy
177,022
+2,164
+1% +$5.05K ﹤0.01% 3943
2022
Q1 		$437K Buy
174,858
+7,095
+4% +$20.1K ﹤0.01% 4003
2021
Q4 		$625K Hold
167,763
– – ﹤0.01% 3931
2021
Q3 		$672K Buy
167,763
+34,194
+26% +$131K ﹤0.01% 3886
2021
Q2 		$594K Buy
133,569
+5,101
+4% +$41.8K ﹤0.01% 3859
2021
Q1 		$1.18M Buy
128,468
+24,769
+24% +$231K ﹤0.01% 3482
2020
Q4 		$1.05M Buy
103,699
+41,037
+65% +$225K ﹤0.01% 3355
2020
Q3 		$265K Buy
62,662
+6,250
+11% +$33.1K ﹤0.01% 3629
2020
Q2 		$390K Sell
56,412
-1,112
-2% -$4.96K ﹤0.01% 3457
2020
Q1 		$161K Buy
57,524
+39,967
+228% +$165K ﹤0.01% 3618
2019
Q4 		$85K Buy
17,557
+2,158
+14% +$6.72K ﹤0.01% 3999
2019
Q3 		$31K Buy
+15,399
New +$49.8K ﹤0.01% 4109

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Geode Capital Management's DMAC Position: Q2 2026 in Review

Geode Capital Management increased its DiaMedica Therapeutics (DMAC) stake by 15% in Q2 2026, buying an estimated $698K and bringing the position to 894,115 shares worth $6.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Geode Capital Management first reported a position in DMAC in Q3 2019 and has held it in 28 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Geode Capital Management held 894,115 shares of DiaMedica Therapeutics worth $6.3M as of Q2 2026.
  • Geode Capital Management bought 113,599 DiaMedica Therapeutics shares in Q2 2026, an estimated $698K.
  • DiaMedica Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2793 holding.
  • Geode Capital Management first reported a position in DiaMedica Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.